
    
      The aim of this study is to evaluate bendamustine, gemcitabine and vinorelbine (BeGEV) scheme
      efficacy as induction therapy to high dose chemotherapy with Allogeneic Hematopoietic
      Stem-Cell Transplantation (AHSCT) for patients with relapsed/refractory Hodglin's Lymphoma
      (HL).

      Four BeGEV courses repeated every 3 weeks in the absence of any reasons listed in the
      paragraph 7.5; whenever an objective response is observed at disease evaluation performed
      after IV cycle patients undergo to high dose chemotherapy with AHSCT (conditioning regimens
      based on preference of each Centre).
    
  